ATE296631T1 - Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation - Google Patents

Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation

Info

Publication number
ATE296631T1
ATE296631T1 AT01983728T AT01983728T ATE296631T1 AT E296631 T1 ATE296631 T1 AT E296631T1 AT 01983728 T AT01983728 T AT 01983728T AT 01983728 T AT01983728 T AT 01983728T AT E296631 T1 ATE296631 T1 AT E296631T1
Authority
AT
Austria
Prior art keywords
premature ejaculation
pde5 inhibitors
treat premature
inhibitors
treat
Prior art date
Application number
AT01983728T
Other languages
English (en)
Inventor
Mitradev Boolell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE296631T1 publication Critical patent/ATE296631T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Soy Sauces And Products Related Thereto (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01983728T 2000-11-20 2001-11-19 Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation ATE296631T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028245.9A GB0028245D0 (en) 2000-11-20 2000-11-20 New therapeutic use
PCT/IB2001/002180 WO2002040027A1 (en) 2000-11-20 2001-11-19 Treatment of premature ejaculation

Publications (1)

Publication Number Publication Date
ATE296631T1 true ATE296631T1 (de) 2005-06-15

Family

ID=9903491

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01983728T ATE296631T1 (de) 2000-11-20 2001-11-19 Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation

Country Status (21)

Country Link
EP (1) EP1335730B1 (de)
JP (1) JP2004520279A (de)
KR (1) KR100595807B1 (de)
CN (1) CN1474692A (de)
AT (1) ATE296631T1 (de)
AU (2) AU1514902A (de)
BR (1) BR0115413A (de)
CA (1) CA2429114C (de)
DE (1) DE60111254T2 (de)
ES (1) ES2240537T3 (de)
GB (1) GB0028245D0 (de)
HU (1) HUP0301915A3 (de)
IL (1) IL155521A0 (de)
MX (1) MXPA03003586A (de)
MY (1) MY131573A (de)
NZ (1) NZ525167A (de)
PL (1) PL362058A1 (de)
PT (1) PT1335730E (de)
TW (1) TWI280132B (de)
WO (1) WO2002040027A1 (de)
ZA (1) ZA200302947B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
EP3646871A1 (de) 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Behandlung und prävention von vorzeitiger ejakulation
CN111297869A (zh) * 2020-04-23 2020-06-19 白文智 一种用于治疗早泄和勃起功能障碍的复方制剂

Also Published As

Publication number Publication date
CA2429114C (en) 2007-09-11
AU2002215149B2 (en) 2006-04-06
ZA200302947B (en) 2004-04-28
CN1474692A (zh) 2004-02-11
TWI280132B (en) 2007-05-01
WO2002040027A1 (en) 2002-05-23
KR100595807B1 (ko) 2006-07-03
PL362058A1 (en) 2004-10-18
CA2429114A1 (en) 2002-05-23
GB0028245D0 (en) 2001-01-03
KR20030048476A (ko) 2003-06-19
EP1335730B1 (de) 2005-06-01
DE60111254T2 (de) 2006-05-04
EP1335730A1 (de) 2003-08-20
ES2240537T3 (es) 2005-10-16
JP2004520279A (ja) 2004-07-08
AU1514902A (en) 2002-05-27
MY131573A (en) 2007-08-30
BR0115413A (pt) 2003-10-07
MXPA03003586A (es) 2003-07-14
PT1335730E (pt) 2005-09-30
HUP0301915A2 (hu) 2003-09-29
DE60111254D1 (de) 2005-07-07
HUP0301915A3 (en) 2007-03-28
NZ525167A (en) 2005-02-25
IL155521A0 (en) 2003-11-23

Similar Documents

Publication Publication Date Title
CY1105390T1 (el) Θepαπευτικη αγωγη της πνευμονικης υπερτασης
DE69911448D1 (de) Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
HRP20040059B1 (hr) Tretman infekcije nokta s no
DE69925970D1 (de) Pyrazolopyrimidinone cGMP PDE5 Inhibitoren zur Behandlung der sexuellen Dysfunktion
EP1129706A3 (de) Verwendung von cGMP-PDE5-Hemmern zur Behandlung der Neuropathie
ATE283856T1 (de) Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
CY1110784T1 (el) Ιατρικη χρηση της τετρα-υδροτριαζολο[4,3-α]πυραζινης
TR200003039T2 (tr) Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri
MY133995A (en) 6-phenylpyrrolopyrimidinedione derivatives
PA8552501A1 (es) 1-alquil o 1-cicloalquil-triazolo[4,3-a]quinazolin-5-onas como inhibidoras de fosfodiesterasa
AU3831301A (en) Method for treating ocular pain
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
NO20024364D0 (no) Anvendelse av pyrido [3,2-E]-pyrazinoner som inhibitorer av fosfodiesterase 5 for behandling av erektil dysfunksjon
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
DE60108068D1 (de) Behandlung diabetischer ulcera
DE60111254D1 (de) Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation
MXPA03010451A (es) Nuevos metodos para el tratamiento y prevencion del dolor.
MY127989A (en) Treatment of neuropathy
UY27411A1 (es) 1-alquil o 1-cicloalquil-triazolo (4, 3-a) quinazolin-5-onas como inhibidoras de fosfodiesterasa.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1335730

Country of ref document: EP

REN Ceased due to non-payment of the annual fee